Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CRU-Ukrainian National Research Center for Radiation Medicine Trio Study

ABSTRACT: CRU-Ukrainian National Research Center for Radiation Medicine Trio Study

PROVIDER: PRJNA327139 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Homo sapiens

Project description:CRU-Ukrainian National Research Center for Radiation Medicine Trio Study

| PRJNA327140 | ENA

Data lab for the national center for scientific and technical research

Project description:Interlab study of rosemary extract in the national center for scientific and technical research 2023

2023-03-09 | MSV000091450 | MassIVE

Recurrent TRIO fusion in non-translocation-related sarcomas

Project description:We used NGS on a cohort of complex genetics sarcomas to study their transcriptomes (RNA-seq technology), looking for recurrent and specific gene fusions. We identified multiple TRIO fusions with different partners in our cohort. No TRIO fusions were reported in negative-control cells (normal tissues) and in simple genetics sarcomas.

2017-03-07 | GSE75885 | GEO

Mutant Mouse Regional Resource Center (MMRRC) Research

Project description:This study is part of the Mutant Mouse Regional Resource Center Research. The series subsets represent the strain and age group for easy comparisons. Each subseries has data for three different tissues (brain, liver and kidney) and 2 sexes. Keywords: other

2005-10-18 | E-GEOD-1920 | biostudies-arrayexpress

Angelman syndrome trio

Project description:Exome sequencing Angelman trio

| PRJEB41088 | ENA

Mutant Mouse Regional Resource Center (MMRRC) Research

2005-10-18 | GSE1920 | GEO

Trio haploinsufficiency causes neurodevelopmental disease-associated deficits

Project description:TMT 11plex-based proteomic and phosphoproteomic analysis of wild type, NEX-Trio+/- and NEX-Trio-/- mouse cortex sections.

2019-01-31 | MSV000083386 | MassIVE

WT1 Trio Peptide-vaccine for Rare Cancers

Project description:Interventions: A patient is vaccinated with Montanide ISA51-adjuvanted WT1 Trio cancer vaccine consisting of two WT1 CTL peptides (WT1-126 and WT1-235) and one WT1 HTL peptide (WT1-332) (2mg each) seven times at the interval of two weeks. Primary outcome(s): Induction of WT1-specific immune responses assessed by WT1-related tests such as WT1-DTH skin reaction and serum levels of WT1 peptide IgG autoantibody at 1M, 2M, and 3M of WT1 Trio vaccine. Study Design: Single arm Non-randomized

| 2638832 | ecrin-mdr-crc

Disease 2020: Large-Scale Sequencing and Analysis Center Initiated Projects/Baylor College of Medicine

Project description:Disease 2020: Large-Scale Sequencing and Analysis Center Initiated Projects/Baylor College of Medicine

| PRJNA252586 | ENA

IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

Project description:IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

| PRJNA606620 | ENA